Spondyloarthritis
sheila RHEUMarampa
3 years 11 months ago
Interim analysis of real world data on AQUILA (Dr Uta Kiltz et al): how gender affects SEC tx and retention rates:
🔷Improvement in BASDAI, PGA, global fnxn & depressive mood - similar in both ♂️&♀️
🔷High SEC retention rates irrespective of gender
@RheumNow #ACR21 abs909 https://t.co/rXa6ELXDJo
sheila RHEUMarampa
3 years 11 months ago
Interesting study by @DrPoddubnyy et al. looking into the efficacy of SEC on HLAB27 subtypes (post hoc analysis of SKIPPAIN trial)
➡ SEC effective for both HLAB27+ and - grps
➡ Significant response seen among HLAB27+ and HLAB27 homozygous pts
@RheumNow #ACR21 abs0917 https://t.co/St37kdGY65
Dr. Antoni Chan synovialjoints
3 years 11 months ago
Radiographic progression in AS is greatest between ages 30-39. The presence of preexisting structural damage starts to accelerate it from earlier ages. Data from 1125 patients followed from 2001-2018 @RheumNow #ACR21 Abst#0897 https://t.co/g0t45R0lOd https://t.co/RvlO9EcMIX
Robert B Chao, MD doctorRBC
3 years 11 months ago
Gender differences in secukinumab treatment of AS?
⭐️improved disease activity, global function, depression in men and women
⭐️women ⬆️disease burden
⭐️high retention rates irrespective of gender
Abs#909
#ACR21 @RheumNow
https://t.co/L6mCxuSMo1 https://t.co/pR3OBoXqaT
Robert B Chao, MD doctorRBC
3 years 11 months ago
Drug retention of TNFi vs. secukinumab in AxSpA pts
Abs#911
⭐️46% discontinued either treatment
⭐️TNFi with slightly better drug retention
⭐️Age, BASDAI, BMI did not favor any group
⭐️inefficacy - main reason
#ACR21 @RheumNow https://t.co/ynoomYrTvX
swethaann23 swethaann23
3 years 11 months ago
Detecting inflammation in SIJ for axSpA is by MRI but Artificial intelligence convolutional network aids this:
-In the Validation set: Trained CNN ▶️91.8% accuracy; Sens 88.9% Sp 93.5%
- Holdout set: 81.5% accuracy; Sens 67%; Sp 84.5%.
Abst# 0905 #ACR21 #ACRBest @RheumNow https://t.co/qmOxk9JQOC
Despite the increasing scientific knowledge on axSpAs, a substantial gap still remains. Delay in diagnosis continues to pose a threat in the early identification of patients and those already on treatment may deal with additional issues such as work productivity or quality of life.
Robert B Chao, MD doctorRBC
3 years 11 months ago
6 year f/up study of sacroilitis in nr-AxSpA pts
⭐️~10% of pts progressed from nr-AxSpa to AS every 2 years
Abs#907
#ACR21
@RheumNow
https://t.co/kiWGmKhpWu
Dr. Antoni Chan synovialjoints
3 years 11 months ago
There are no MRI imaging difference in axSpA with psoriasis, coliitis or iritis. 240 patients in the SASPIC study show psoriatic axSpA similar to axSpA associated with iritis or colitis. Supports the umbrella concept of axSpA @RheumNow #ACR21 Abst#0902 https://t.co/VKTUv22hEJ https://t.co/lOL82ceSn9
Robert B Chao, MD doctorRBC
3 years 11 months ago
Great start to #ACR21 and great recap of the year in rheumatology.
Positive data on tofacitinib and AS but still pending approval.
Where would JAKinibs be in your AS treatment algorithm?🤔
@RheumNow https://t.co/cs8U33355A
Eric Dein ericdeinmd
3 years 11 months ago
#ACR21 Abst#0910 by @rheum_cat. Do TNFi ⬆️ risk of incident HTN in AxSpa?
⭐️PSOAS cohort: Prosp study from 2003-2018
▶️When adjusted for confounders (obesity, disease activity, NSAID use), insufficient evidence to show ⬆️ risk of HTN w TNFi
https://t.co/DCZ3W8CkOa @Rheumnow
Poster Hall